AbbVie gets FDA OK for antibiotic treatment

 

• EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria
• Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies
• Antimicrobial resistance (AMR) could lead to over 39 million deaths worldwide by 2050, and new treatments are urgently needed1

https://www.prnewswire.com/news-releases/us-fda-approves-emblaveo-aztreonam-and-avibactam-for-the-treatment-of-adults-with-complicated-intra-abdominal-infections-with-limited-or-no-treatment-options-302371478.html